

## Audited Financial Results for the Year ended 31st March, 2010

(Rs. in Lacs)

(Rs. in Lacs)

CONSOLIDATED RESULTS				Particulars	JUBILANT ORGANOSYS LTD.			
Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)			Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)	
2010	2009	2010	2009		2010	2009	2010	2009
99032	84124	378127	351798	<b>Net sales/Income from operations</b>	60041	54806	244620	243072
400	243	1740	2434	Other Operating Income	442	129	1414	1138
99432	84367	379867	354232	<b>Total income</b>	60483	54935	246034	244210
80317	79340	311726	310893	<b>Total expenditure</b>	46297	54495	189009	208352
(4109)	(1868)	(2038)	(7813)	a) (Increase)/Decrease in stock in trade and work in progress	(3593)	2294	(1646)	(2811)
6579	2418	20185	11349	b) Purchase of traded goods	4771	3339	17531	10668
35287	29138	129043	131488	c) Raw & process materials consumed	27516	23804	105344	113470
6811	5014	23716	21116	d) Stores, spares, chemicals, catalyst & packing material consumed	3351	2352	11608	11666
5594	3882	22003	19791	e) Power & fuel	4997	3462	19946	18079
2243	2049	7327	7957	f) Other manufacturing expenses	1525	1742	5328	6364
18478	17780	74526	65749	g) Staff cost	4279	3684	17600	15600
3184	4509	12468	16324	h) Depreciation	1668	2094	6510	7462
6250	16418	24496	44932	i) Selling, general & admin. Expenses (Including Exchange Loss/Gain)	1783	11724	6788	27854
19115	5027	68141	43339	<b>Operating profit before Other Income &amp; Interest</b>	14186	440	57025	35858
410	1027	1986	1816	Other Income	277	406	1154	674
19525	6054	70127	45155	<b>Profit before Interest &amp; Exceptional Items</b>	14463	846	58179	36532
3452	3883	15052	10704	Interest (Net)	1797	2722	9971	5435
16073	2171	55075	34451	<b>Profit after Interest but before Exceptional Items</b>	12666	(1876)	48208	31097
(169)	3692	3286	4793	Exceptional items	2	2693	2281	3794
16242	(1521)	51789	29658	<b>Profit from Ordinary Activities before tax</b>	12664	(4569)	45927	27303
2711	(2426)	9594	2672	Tax Expenses (Net)	3463	(3040)	9617	1229
13531	905	42195	26986	<b>Net profit from Ordinary Activities after tax</b>	9201	(1529)	36310	26074
-	-	-	-	Extraordinary Items (net of tax expenses)	-	-	-	-
(185)	(332)	49	(1332)	Minority Interest	-	-	-	-
13716	1237	42146	28318	<b>Net profit after Minority Interest</b>	9201	(1529)	36310	26074
1588	1475	1588	1475	Paid-up share capital (Face value per share Re.1)	1588	1475	1588	1475
		218546	152789	Reserves (excluding revaluation reserve & FCMITDA)			215697	148423
9.29	0.84	28.56	19.22	Earnings per share before and after extraordinary items (Not annualized)	6.23	(1.04)	24.60	17.70
8.03	0.72	24.66	16.56	<b>Basic (Rs.)</b>	5.38	(0.89)	21.24	15.25
				<b>Diluted (Rs.)</b>				
				<b>Public shareholding</b>				
83627751	73121834	83627751	73121834	- Number of shares (Re. 1 each)	83627751	73121834	83627751	73121834
52.67	49.56	52.67	49.56	- Percentage of shareholding	52.67	49.56	52.67	49.56
				<b>Promoters and promoter group Shareholding</b>				
				<b>a) Pledged/Encumbered</b>				
14245000	16421000	14245000	16421000	- Number of shares	14245000	16421000	14245000	16421000
18.95	22.07	18.95	22.07	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	18.95	22.07	18.95	22.07
8.97	11.13	8.97	11.13	- Percentage of shares (as a % of the total share capital of the company)	8.97	11.13	8.97	11.13
				<b>b) Non-Encumbered</b>				
60907024	57999424	60907024	57999424	- Number of shares	60907024	57999424	60907024	57999424
81.05	77.93	81.05	77.93	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	81.05	77.93	81.05	77.93
38.36	39.31	38.36	39.31	- Percentage of shares (as a % of the total share capital of the company)	38.36	39.31	38.36	39.31

- Notes:**
- The company allotted 11,237,517 Nos equity Shares of Rs.1 each at a premium of Rs.343.50 to Qualified Institutional Buyers (QIB) on 31st March, 2010.
  - The Board has recommended a dividend of Rs.2.00 per equity shares of Rs.1 amounting to Rs.3703 Lacs, subject to approval in the Annual General Meeting.
  - In order to bring uniformity in accounting policy, beginning 1st April, 2009, the depreciation method, in respect of certain assets has been changed from written down value method to straight line method with retrospective effect as per AS 6 and consequent effect is cumulative lower depreciation charge by Rs.3116 Lacs (Consolidated Rs.6747 Lacs). Due to the effect of such change in the policy, the depreciation charge for the year is lower by Rs.3471 Lacs (Consolidated Rs.7390 Lacs).
  - The company had opted for accounting of exchange difference arising on reporting of long term monetary items under AS 11 in line with the Companies (Accounting Standard) Amendment Rules 2009 in Q4- FY 2009 and net exchange loss amounting to Rs.11308 Lacs (Consolidated Rs.11308 Lacs) was capitalised to the cost of fixed assets and Rs.15960 Lacs (Consolidated Rs.27509 Lacs) was debited Foreign Currency Monetary Items Translation Difference Account (FCMITDA). During the year Rs.15374 Lacs (Consolidated - Rs.26301 Lacs) were reversed from FCMITDA on account of Foreign exchange gain / amortisation. The balance in FCMITDA amounting to Rs.586 Lacs (Consolidated Rs.1208 Lacs) subject to further fluctuations on reporting date will be amortised till March 2011.

Segment wise Revenue, Results & Capital Employed (under Clause 41 of the Listing Agreement)								
CONSOLIDATED RESULTS				Particulars	JUBILANT ORGANOSYS LTD.			
Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)			Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)	
2010	2009	2010	2009		2010	2009	2010	2009
89849	74601	336630	297545	<b>Segment revenue</b>	50913	45542	203266	188794
9271	9601	41951	54651	a. Pharmaceuticals and Life Sciences Products & Services	9216	9342	41808	54676
99120	84202	378581	352196	b. Agri & Performance Polymers	60129	54884	245074	243470
88	78	454	398	<b>Total</b>	88	78	454	398
99032	84124	378127	351798	Less : Inter segment revenue	99032	84124	378127	351798
89761	74523	336176	297147	<b>Net sales/Income from operations</b>	60041	54806	244620	243072
9271	9601	41951	54651	a. Pharmaceuticals and Life Sciences Products & Services	50825	45464	202812	188396
99032	84124	378127	351798	b. Agri & Performance Polymers	9216	9342	41808	54676
				<b>Total</b>	60041	54806	244620	243072
				<b>Segment results (profit+)/loss(-) before tax and interest from each segment</b>				
20437	9973	75130	49186	a. Pharmaceuticals and Life Sciences Products & Services	15359	4773	63172	40660
1012	1	1899	3968	b. Agri & Performance Polymers	1026	6	1908	4073
21449	9974	77029	53154	<b>Total</b>	16385	4779	65080	44733
3452	3883	15052	10704	Less : i. Interest	1797	2722	9971	5435
1756	13923	12250	19636	ii. Other un-allocable expenditure (including exceptional items)	1925	12927	11244	18577
(1)	(6311)	(2062)	(6844)	iii. Un-allocable Income (including exceptional items)	(1)	(6301)	(2062)	(6582)
16242	(1521)	51789	29658	<b>Total profit before tax</b>	12664	(4569)	45927	27303
				<b>Capital Employed (Segment assets less Segment liabilities)</b>				
469012	471830	469012	471830	a. Pharmaceuticals and Life Sciences Products & Services	178632	183306	178632	183306
21481	19061	21481	19061	b. Agri & Performance Polymers	21344	18815	21344	18815
490493	490891	490493	490891	<b>Total Capital employed in segments</b>	199976	202121	199976	202121
68739	44745	68739	44745	Add: Un-allocable corporate assets less liabilities	238448	197038	238448	197038
559232	535636	559232	535636	<b>Total capital employed in the Company</b>	438424	399159	438424	399159

Statement of Assets And Liabilities (Rs. in Lacs)				
CONSOLIDATED		Particulars	JUBILANT ORGANOSYS LTD.	
As At March 31 (Audited)			As At March 31 (Audited)	
2010	2009		2010	2009
1588	1476	<b>Share holders Funds</b>	1588	1476
218546	152789	a) Capital	215697	148423
3792	3195	b) Reserves and Surplus	-	-
311999	387811	Minority Interest	201227	252564
5273	6368	Loan from Banks, Institutions and FCCB's	-	-
19242	11506	Loan from Customers	20498	12656
560440	563145	Deferred Tax Liabilities		
		<b>TOTAL</b>	439010	415119
432452	424812	<b>Fixed Assets</b>	173144	166587
22371	23813	a) Investments-In Liquid Funds	18622	23010
3270	3323	b) Investments-Others	168298	147944
1208	27509	Foreign Currency Monetary Items Translation Difference Account (FCMITDA)	586	15960
69095	59561	<b>Current Assets, Loans and Advances</b>		
51861	50441	a) Inventories	42471	33343
50367	38167	b) Sundry Debtors	30730	35595
		c) Cash and Bank balances	43422	27893
		d) Other current assets		
51827	48549	e) Loans and Advances	58434	47308
		Less : Current Liabilities and Provisions		
75352	67278	a) Liabilities	51955	40376
46659	45785	b) Provisions	44742	42178
-	33	Miscellaneous Expenditure (Not Written Off or Adjusted)	-	33
560440	563145	<b>TOTAL</b>	439010	415119

- In line with the continued strategy to make the company a focused Pharma and Life Sciences Company, the Board has in principle approved business restructuring involving demerger of Agri and Performance Polymers business into a separate company. Accordingly the reporting segments have been redefined as Pharmaceuticals and Life Sciences Products and Services (PLSPS) and Agri & Performance Polymers (APP) to reflect the results of these two businesses separately. The demerger will be carried out through a court scheme and is subject to necessary regulatory and other approvals/sanctions.
- Exceptional items include : i) Amortisation of Foreign Currency Monetary item Translation Difference Account, Rs.- 1400 Lacs (Consolidated Rs.- 1766 Lacs) for Q4-FY 2010 and Rs.1008 Lacs (Consolidated Rs.1621 Lacs) for FY 2010. ii) Movement in Mark to Market(MTM) of unassigned forward contracts/interest rate swap outstanding at the period end resulting in Loss amounting to Rs.762 Lacs (Consolidated loss amounting to Rs.933 Lacs) for Q4-FY 2010 and loss amounting to Rs.633 Lacs (Consolidated - loss amounting to Rs.1001 Lacs) for FY 2010.
- Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New - 22, Disposals - 22, Closing Balance - Nil.
- Previous year / periods figures have been regrouped/reclassified wherever necessary.
- The above Financial results were approved by the Board of Directors at its meeting held on 10th May, 2010.

For Jubilant Organosys Ltd.